We are monitoring the impact of COVID-19 on North America Checkpoint Inhibitors Market Get in touch with us for detailed analysis Know More
Share on

North America Checkpoint Inhibitors Market Research Report – Segmented By Type, Application & Country (The United States, Canada & Rest of North America) - Industry Analysis on Size, Share, Trends & Growth Forecast (2022 to 2027)

Published: January, 2022
ID: 2085
Pages: 145

North America Checkpoint Inhibitors Market Size (2022 to 2027)

The size of the North America Checkpoint Inhibitors Market is estimated to be growing at a CAGR of 27.80% during the forecast period. The market size is estimated to grow USD 13.07 billion by 2027 from USD 3.83 billion in 2022.

The proliferation of cancer is a growth factor to the Checkpoint Inhibitors market in North America. The rise in the prevalence of cancer across the region and increase in awareness about checkpoint Inhibitors are projected to fuel the market during the forecast period. However, technological advancements in the healthcare sector, such as screening procedures for cancer and government initiatives to alleviate cancer, are likely to augment the market growth. 

In addition, increasing healthcare expenditure and implementation of research and development activities by the major companies in the region are providing lucrative growth opportunities for the market players. Furthermore, an increase in investment and funding by the government and non-government organizations enables the entry of new market entrants, which most likely expand the regional market growth. 

Over the years, the major companies in the checkpoint inhibitor market in the region are forming partnerships or collaborations to develop advanced technologies such as bifunctional fusion protein or Y-trap. Bifunctional fusion protein or Y-trap is a therapy that was developed. But, unfortunately, most patients with cancer do not respond to immune checkpoint inhibitors.

In the year 2018, researchers created the bifunctional fusion protein or Y-trap to improve the efficacy of immunotherapies. This medication is made by fusing a receptor for TGF-beta, a protein that targets checkpoint proteins including PD-L1 and CTLA-4. As a result, y- Trap targets both a checkpoint inhibitor and TGF-beta, providing a more effective approach to prevent immune suppression while also destroying the c-Reactive protein. 

However, the high cost associated with research activities is projected to restrain the market growth. Also, the lack of awareness and proper publicity for using these inhibitors in some areas restricts the North America Checkpoint Inhibitors Market growth. 

This research report on the North America Checkpoint Inhibitors Market has been segmented and sub-segmented into the following categories.

By Drug: 

  • PD-1 inhibitors
  • PD-L1 inhibitors
  • CTLA-4
  • Chimeric Antigen Receptor T-cell
  • Others

By Application: 

  • Lung cancer
  • Renal cancer
  • Blood cancer
  • Bladder Cancer
  • Hodgkin lymphoma
  • Melanoma
  • Others

By Country: 

  • The United States
  • Canada
  • Rest of North America

Geographically, the North American market is forecasted to dominate the global checkpoint inhibitors market over the forecast period. The growing population is the factor leading to an increase in hospitals and diagnostic centers in North America. Also, the increasing number of cancer incidences and rising government initiatives to improve awareness about diagnosis and treatment boost market growth. Over the forecast period, the immune checkpoint inhibitors market is dominated by Lung Cancer & Melanoma applications. In addition, several companies and academic institutions focus on novel treatment approaches, thus contributing to the immune checkpoint inhibitors market in North America. The United States and Canada are the two most significant market growth contributors in the region, expanding the North American Checkpoint Inhibitors Market. over the forecast period, the United States dominated the market and is most likely to continue its growth during the forecast period. Advanced healthcare infrastructure, favorable reimbursement policies, and technological advancements are majorly propelling the market growth. According to the American Cancer Society, 1.7 million new cancer cases and 0.6 million cancer deaths occurred in the United States in 2019. Lung, prostate, bowel, and female breast cancer are the four most prevalent malignancies globally, accounting for 43 percent of all new cancer cases. Checkpoint inhibitors that target the checkpoints are effective cancer treatments. As a result, the increase in cancer incidence rates in North America is expected to drive demand for checkpoint inhibitors.

KEY MARKET PLAYERS:

A few of the key market participants operating in the North America Checkpoint Inhibitors Market are Merck & Co., Inc., Bristol-Myers Squibb, Roche, AstraZeneca, Ono Pharmaceutical Co., Ltd., Juno Therapeutics, Novartis International AG, and Kite Pharma.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                          

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                               

                2.2 Research Phases                      

                                2.2.1 Secondary Research           

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling      

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                       

                3.1 Executive Summary                

                3.2 Key Inferences                         

                3.3 Epidemology                              

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                    

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market                              

5. Market Segmentation                                              

                5.1 Drug Type                   

                                5.1.1 Introduction           

                                5.1.2 PD-1 inhibitors       

                                5.1.3 PD-L1 inhibitors     

                                5.1.4 CTLA-4      

                                5.1.5  Chimeric Antigen Receptor T-cell 

                                5.1.6  Others     

                                5.1.7 Y-o-Y Growth Analysis, By Drug Type           

                                5.1.8 Market Attractiveness Analysis, By Drug Type         

                                5.1.9 Market Share Analysis, By Drug Type          

                5.2 Application                 

                                5.2.1 Introduction           

                                5.2.2 Lung cancer            

                                5.2.3 Renal cancer           

                                5.2.4 Blood cancer          

                                5.2.5 Bladder Cancer      

                                5.2.6  Hodgkin lymphoma            

                                5.2.7 Melanoma              

                                5.2.8  Others     

                                5.2.9 Y-o-Y Growth Analysis, By Application         

                                5.2.10  Market Attractiveness Analysis, By Application   

                                5.2.11  Market Share Analysis, By Application     

6. Geographical Analysis                                              

                6.1 Introduction                               

                                6.1.1 Regional Trends    

                                6.1.2 Impact Analysis     

                                6.1.3 Y-o-Y Growth Analysis        

                                                6.1.3.1 By Geographical Area

                                                6.1.3.2 By Drug Type

                                                6.1.3.3 By Application

                                6.1.4  Market Attractiveness Analysis     

                                                6.1.4.1 By Geographical Area

                                                6.1.4.2 By Drug Type

                                                6.1.4.3 By Application

                                6.1.5  Market Share Analysis      

                                                6.1.5.1 By Geographical Area

                                                6.1.5.2 By Drug Type

                                                6.1.5.3 By Application

                6.2 United States                            

                6.3 Canada                         

7.Strategic Analysis                                        

                7.1 PESTLE analysis                         

                                7.1.1 Political     

                                7.1.2 Economic 

                                7.1.3 Social         

                                7.1.4 Technological         

                                7.1.5 Legal          

                                7.1.6 Environmental       

                7.2 Porter’s Five analysis                              

                                7.2.1 Bargaining Power of Suppliers        

                                7.2.2 Bargaining Power of Consumers    

                                7.2.3 Threat of New Entrants     

                                7.2.4 Threat of Substitute Products and Services              

                                7.2.5 Competitive Rivalry within the Industry     

8.Market Leaders' Analysis                                         

                8.1 Merck & Co., Inc.                     

                                8.1.1 Overview 

                                8.1.2 Product Analysis   

                                8.1.3 Financial analysis  

                                8.1.4 Recent Developments       

                                8.1.5 SWOT analysis       

                                8.1.6 Analyst View          

                8.2 Bristol-Myers Squibb                              

                8.3 Roche                           

                8.4 AstraZeneca                               

                8.5 Ono Pharmaceutical Co., Ltd.                              

                8.6  Juno Therapeutics                  

                8.7 Novartis International AG                    

                8.8 Kite Pharma                               

9.Competitive Landscape                                            

                9.1 Market share analysis                            

                9.2 Merger and Acquisition Analysis                       

                9.3 Agreements, collaborations and Joint Ventures                         

                9.4 New Product Launches                         

10.Market Outlook and Investment Opportunities                                          

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  1. North America Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Million)
  2. North America PD-1 inhibitors Market, By Region, From 2022 - 2027 (USD Million)
  3. North America PD-L1 inhibitors Market, By Region, From 2022 - 2027 (USD Million)
  4. North America CTLA-4 Market, By Region, From 2022 - 2027 (USD Million)
  5. North America Chimeric Antigen Receptor T-cell Market, By Region, From 2022 - 2027 (USD Million)
  6. North America Others Market, By Region, From 2022 - 2027 (USD Million)
  7. North America Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Million)
  8. North America Lung cancer Market, By Region, From 2022 - 2027 (USD Million)
  9. North America Renal cancer Market, By Region, From 2022 - 2027 (USD Million)
  10. North America Blood cancer Market, By Region, From 2022 - 2027 (USD Million)
  11. North America Bladder Cancer Market, By Region, From 2022 - 2027 (USD Million)
  12. North America Hodgkin lymphoma Market, By Region, From 2022 - 2027 (USD Million)
  13. North America Melanoma Market, By Region, From 2022 - 2027 (USD Million)
  14. North America Others Market, By Region, From 2022 - 2027 (USD Million)
  15. United States Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Million)
  16. United States Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Million)
  17. Canada Checkpoint Inhibitors Market, By Drug Type, From 2022 - 2027 (USD Million)
  18. Canada Checkpoint Inhibitors Market, By Application, From 2022 - 2027 (USD Million)

Please wait. . . . Your request is being processed

Related Reports

PURCHASE OPTIONS

excel
$

3335


pdf excel
$

3680


pdf excel powerbi
$

5520


excel
$

2000

What You Get :

  • PDF Report Format.
  • Can be accessible by 1 single user.
  • 6 Months of Free Analyst Support.
  • PDF and Excel Datasheet Formats.
  • Can be accessible upto 2 to 5 users.
  • 1 Year of Free Analyst Support.
  • PDF, Excel and Power BI Dashboard.
  • Can be accessible by unlimited users.
  • 1 Year of Free Analyst Support.
  • Excel Datasheet Format.
  • Customized access as per user request.
  • Upgradable to other licenses.
customer-support
ASK FOR CUSTOMIZATION

Talk to our analyst and get customised report done according to your research needs

tag
INQUIRE FOR DISCOUNT

Check if you can avail any discount. Submit your details and our team will get back to you.

cloud-download
DOWNLOAD FREE SAMPLE

Request to avail a free sample report that reflects this market and its growth.

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 3335

Didn’t find what you’re looking for?
TALK TO OUR TEAM

Find it too expensive?
NO WORRIES!

Click for Request Sample